Sarepta Therapeutics (NASDAQ:SRPT) Director Sells $123,207.78 in Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Stephen Mayo sold 7,239 shares of the stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $17.02, for a total value of $123,207.78. Following the completion of the transaction, the director directly owned 1,765 shares of the company’s stock, valued at $30,040.30. This represents a 80.40% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Sarepta Therapeutics Trading Down 3.8%

SRPT opened at $16.40 on Monday. The company has a quick ratio of 1.48, a current ratio of 2.32 and a debt-to-equity ratio of 0.73. Sarepta Therapeutics, Inc. has a 52 week low of $10.41 and a 52 week high of $103.32. The stock has a market cap of $1.72 billion, a PE ratio of -1.94, a PEG ratio of 0.24 and a beta of 0.42. The business has a 50 day moving average of $19.43 and a 200-day moving average of $20.00.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The firm had revenue of $442.93 million during the quarter, compared to analysts’ expectations of $390.95 million. Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.Sarepta Therapeutics’s revenue for the quarter was down 32.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.90 earnings per share. Equities research analysts predict that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

SRPT has been the topic of a number of recent research reports. Mizuho upped their target price on shares of Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a research report on Thursday. HC Wainwright reissued a “sell” rating on shares of Sarepta Therapeutics in a research report on Monday, March 2nd. Wall Street Zen raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Barclays started coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 28th. They issued an “equal weight” rating and a $20.00 price objective on the stock. Finally, Citigroup raised their target price on shares of Sarepta Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a research note on Tuesday, March 10th. Nine research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $32.15.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds have recently bought and sold shares of the company. Kestra Advisory Services LLC purchased a new position in Sarepta Therapeutics in the fourth quarter worth about $25,000. iSAM Funds UK Ltd purchased a new stake in shares of Sarepta Therapeutics during the third quarter valued at approximately $25,000. Ancora Advisors LLC increased its position in shares of Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 1,000 shares in the last quarter. Byrne Asset Management LLC bought a new stake in shares of Sarepta Therapeutics during the third quarter valued at approximately $33,000. Finally, Allworth Financial LP raised its holdings in Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 1,721 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.